{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:01:28Z","timestamp":1794852088851,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R01-AI146101"],"award-info":[{"award-number":["NIH R01-AI146101"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R01-AI146101"],"award-info":[{"award-number":["NIH R01-AI146101"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00051"],"award-info":[{"award-number":["75N93019C00051"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of a universal influenza virus vaccine with the potential to elicit long-lasting, broadly cross-reactive immune responses is a necessity for reducing influenza-associated morbidity and mortality. Here we focus on the development of a universal influenza B virus vaccine based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate vaccine candidates based on different target antigens that afford protection against challenge with ancestral and recent influenza B viruses from both antigenic lineages. A pentavalent vaccine combining all tested antigens protects mice from morbidity at a very low dose of 50\u2009ng per antigen after a single vaccination. These findings support the further advancement of nucleoside-modified mRNA-LNPs expressing multiple conserved antigens as universal influenza virus vaccine candidates.<\/jats:p>","DOI":"10.1038\/s41467-022-32149-8","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T17:12:36Z","timestamp":1660065156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1008-6242","authenticated-orcid":false,"given":"Norbert","family":"Pardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"O\u2019Dell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8269-5560","authenticated-orcid":false,"given":"Jessica","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"Bajusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn","family":"Rijnink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Strohmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-8036","authenticated-orcid":false,"given":"Madhumathi","family":"Loganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Bielak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0874-0922","authenticated-orcid":false,"given":"Molly M. H.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying K.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7450-6624","authenticated-orcid":false,"given":"Meagan","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"32149_CR1","doi-asserted-by":"publisher","first-page":"e0222381","DOI":"10.1371\/journal.pone.0222381","volume":"14","author":"S Caini","year":"2019","unstructured":"Caini, S. et al. The epidemiological signature of influenza B virus and its B\/Victoria and B\/Yamagata lineages in the 21st century. PLoS One 14, e0222381 (2019).","journal-title":"PLoS One"},{"key":"32149_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4621-z","volume":"19","author":"S Puzelli","year":"2019","unstructured":"Puzelli, S. et al. Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017. BMC Infect. Dis. 19, 990 (2019).","journal-title":"BMC Infect. Dis."},{"key":"32149_CR3","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1073\/pnas.1916585116","volume":"117","author":"RK Virk","year":"2020","unstructured":"Virk, R. K. et al. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity. Proc. Natl Acad. Sci. USA 117, 619\u2013628 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32149_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/14737167.2017.1343145","volume":"17","author":"PT de Boer","year":"2017","unstructured":"de Boer, P. T. et al. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Rev. Pharmacoecon Outcomes Res 17, 249\u2013265 (2017).","journal-title":"Expert Rev. Pharmacoecon Outcomes Res"},{"key":"32149_CR5","doi-asserted-by":"publisher","first-page":"e02556","DOI":"10.1128\/mBio.02556-14","volume":"6","author":"TJ Wohlbold","year":"2015","unstructured":"Wohlbold, T. J. et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio 6, e02556 (2015).","journal-title":"MBio"},{"key":"32149_CR6","doi-asserted-by":"publisher","first-page":"e00560","DOI":"10.1128\/mBio.00560-19","volume":"10","author":"M McMahon","year":"2019","unstructured":"McMahon, M. et al. Mucosal immunity against neuraminidase prevents influenza B virus transmission in guinea pigs. mBio 10, e00560\u201300519 (2019).","journal-title":"mBio"},{"key":"32149_CR7","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. Antibody responses towards the major antigenic sites of influenza B virus hemagglutinin in mice, ferrets and humans. J. Virol. https:\/\/doi.org\/10.1128\/jvi.01673-18 (2018).","DOI":"10.1128\/jvi.01673-18"},{"key":"32149_CR8","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41564-017-0011-8","volume":"2","author":"TJ Wohlbold","year":"2017","unstructured":"Wohlbold, T. J. et al. Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes. Nat. Microbiol. 2, 1415\u20131424 (2017).","journal-title":"Nat. Microbiol."},{"key":"32149_CR9","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.immuni.2020.08.015","volume":"53","author":"A Madsen","year":"2020","unstructured":"Madsen, A. et al. Human antibodies targeting influenza B virus neuraminidase active site are broadly protective. Immunity 53, 852\u2013863.e857 (2020).","journal-title":"Immunity"},{"key":"32149_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cid\/cis327","volume":"55","author":"PJ Lillie","year":"2012","unstructured":"Lillie, P. J. et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 55, 19\u201325 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"32149_CR11","doi-asserted-by":"publisher","unstructured":"McMahon, M. et al. Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 antigens protects ferrets against influenza virus challenge. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02005 (2019).","DOI":"10.3389\/fimmu.2019.02005"},{"key":"32149_CR12","doi-asserted-by":"publisher","unstructured":"Sun, W., Zheng, A., Miller, R., Krammer, F. & Palese, P. An inactivated influenza virus vaccine approach to targeting the conserved hemagglutinin stalk and M2e domains. Vaccines (Basel) https:\/\/doi.org\/10.3390\/vaccines7030117 (2019).","DOI":"10.3390\/vaccines7030117"},{"key":"32149_CR13","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569\u20131584, https:\/\/doi.org\/10.1016\/j.ymthe.2020.04.018 (2020).","journal-title":"Mol. Ther."},{"key":"32149_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.omtm.2021.06.003","volume":"22","author":"AW Freyn","year":"2021","unstructured":"Freyn, A. W. et al. Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice. Mol. Ther. Methods Clin. Dev. 22, 84\u201395, https:\/\/doi.org\/10.1016\/j.omtm.2021.06.003 (2021).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"32149_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med"},{"key":"32149_CR16","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med"},{"key":"32149_CR17","doi-asserted-by":"publisher","unstructured":"Chen, Y. Q., Lan, L. Y., Huang, M., Henry, C. & Wilson, P. C. Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance. J. Virol. https:\/\/doi.org\/10.1128\/jvi.01526-18 (2019).","DOI":"10.1128\/jvi.01526-18"},{"key":"32149_CR18","doi-asserted-by":"publisher","first-page":"e1009407","DOI":"10.1371\/journal.ppat.1009407","volume":"17","author":"CD Lee","year":"2021","unstructured":"Lee, C. D. et al. A cross-neutralizing antibody between HIV-1 and influenza virus. PLoS Pathog. 17, e1009407 (2021).","journal-title":"PLoS Pathog."},{"key":"32149_CR19","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","volume":"215","author":"N Pardi","year":"2018","unstructured":"Pardi, N. et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med 215, 1571\u20131588 (2018).","journal-title":"J. Exp. Med"},{"key":"32149_CR20","doi-asserted-by":"publisher","unstructured":"Alameh, M. G., Weissman, D. & Pardi, N. Messenger RNA-based vaccines against infectious diseases. Curr. Top Microbiol. Immunol. https:\/\/doi.org\/10.1007\/82_2020_202 (2020).","DOI":"10.1007\/82_2020_202"},{"key":"32149_CR21","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4049\/jimmunol.1801149","volume":"202","author":"A Zhang","year":"2019","unstructured":"Zhang, A., Stacey, H. D., Mullarkey, C. E. & Miller, M. S. Original antigenic sin: how first exposure shapes lifelong anti-influenza virus immune responses. J. Immunol. 202, 335\u2013340 (2019).","journal-title":"J. Immunol."},{"key":"32149_CR22","first-page":"1365","volume":"326","author":"J Abbasi","year":"2021","unstructured":"Abbasi, J. Moderna\u2019s mRNA vaccine for seasonal flu enters clinical trials. JAMA 326, 1365\u20131365 (2021).","journal-title":"JAMA"},{"key":"32149_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med 27, 106\u2013114 (2021).","journal-title":"Nat. Med"},{"key":"32149_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0026-4","volume":"2","author":"R Nachbagauer","year":"2017","unstructured":"Nachbagauer, R. et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines 2, 26 (2017).","journal-title":"NPJ Vaccines"},{"key":"32149_CR25","doi-asserted-by":"publisher","unstructured":"Nachbagauer, R. et al. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. NPJ Vaccines https:\/\/doi.org\/10.1038\/npjvaccines.2016.15 (2016).","DOI":"10.1038\/npjvaccines.2016.15"},{"key":"32149_CR26","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1128\/JVI.03183-13","volume":"88","author":"F Krammer","year":"2014","unstructured":"Krammer, F. et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J. Virol. 88, 2340\u20132343 (2014).","journal-title":"J. Virol."},{"key":"32149_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26538-7","volume":"8","author":"HM Yassine","year":"2018","unstructured":"Yassine, H. M. et al. Use of hemagglutinin stem probes demonstrate prevalence of broadly reactive group 1 influenza antibodies in human sera. Sci. Rep. 8, 8628 (2018).","journal-title":"Sci. Rep."},{"key":"32149_CR28","doi-asserted-by":"publisher","unstructured":"Darricarr\u00e8re, N. et al. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. Sci. Transl. Med. https:\/\/doi.org\/10.1126\/scitranslmed.abe5449 (2021).","DOI":"10.1126\/scitranslmed.abe5449"},{"key":"32149_CR29","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio https:\/\/doi.org\/10.1128\/mBio.02810-18 (2019).","DOI":"10.1128\/mBio.02810-18"},{"key":"32149_CR30","doi-asserted-by":"publisher","unstructured":"Ermler, M. E. et al. Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00286-17 (2017).","DOI":"10.1128\/jvi.00286-17"},{"key":"32149_CR31","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. Development of influenza B universal vaccine candidates using the \u201cmosaic\u201d hemagglutinin approach. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00333-19 (2019).","DOI":"10.1128\/jvi.00333-19"},{"key":"32149_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08165-y","volume":"10","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Cross-lineage protection by human antibodies binding the influenza B hemagglutinin. Nat. Commun. 10, 324 (2019).","journal-title":"Nat. Commun."},{"key":"32149_CR33","doi-asserted-by":"publisher","first-page":"5567","DOI":"10.1016\/j.vaccine.2019.07.095","volume":"37","author":"G Asthagiri Arunkumar","year":"2019","unstructured":"Asthagiri Arunkumar, G. et al. Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice. Vaccine 37, 5567\u20135577 (2019).","journal-title":"Vaccine"},{"key":"32149_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciq015","volume":"52","author":"TK Berthoud","year":"2011","unstructured":"Berthoud, T. K. et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 52, 1\u20137 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"32149_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/srep24402","volume":"6","author":"M Schotsaert","year":"2016","unstructured":"Schotsaert, M. et al. Long-lasting cross-protection zgainst influenza A by neuraminidase and M2e-based immunization strategies. Sci. Rep. 6, 24402 (2016).","journal-title":"Sci. Rep."},{"key":"32149_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.09.6","volume":"8","author":"M Schotsaert","year":"2009","unstructured":"Schotsaert, M., De Filette, M., Fiers, W. & Saelens, X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev. Vaccines 8, 499\u2013508 (2009).","journal-title":"Expert Rev. Vaccines"},{"key":"32149_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.antiviral.2019.01.002","volume":"163","author":"MH Kim","year":"2019","unstructured":"Kim, M. H. et al. Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus. Antivir. Res. 163, 19\u201328 (2019).","journal-title":"Antivir. Res."},{"key":"32149_CR38","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/CVI.00339-13","volume":"20","author":"R Bodewes","year":"2013","unstructured":"Bodewes, R. et al. In vitro assessment of the immunological significance of a human monoclonal antibody directed to the influenza a virus nucleoprotein. Clin. Vaccin. Immunol. 20, 1333\u20131337 (2013).","journal-title":"Clin. Vaccin. Immunol."},{"key":"32149_CR39","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/imcb.12508","volume":"100","author":"HA Vanderven","year":"2022","unstructured":"Vanderven, H. A. et al. Poor protective potential of influenza nucleoprotein antibodies despite wide prevalence. Immunol. Cell Biol. 100, 49\u201360 (2022).","journal-title":"Immunol. Cell Biol."},{"key":"32149_CR40","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.vaccine.2006.08.036","volume":"25","author":"JH Kreijtz","year":"2007","unstructured":"Kreijtz, J. H. et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25, 612\u2013620 (2007).","journal-title":"Vaccine"},{"key":"32149_CR41","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1128\/JVI.72.7.5648-5653.1998","volume":"72","author":"JB Ulmer","year":"1998","unstructured":"Ulmer, J. B. et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J. Virol. 72, 5648\u20135653 (1998).","journal-title":"J. Virol."},{"key":"32149_CR42","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1164\/rccm.201411-1988OC","volume":"191","author":"AC Hayward","year":"2015","unstructured":"Hayward, A. C. et al. Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu watch cohort study. Am. J. Respir. Crit. Care Med 191, 1422\u20131431 (2015).","journal-title":"Am. J. Respir. Crit. Care Med"},{"key":"32149_CR43","doi-asserted-by":"crossref","unstructured":"Clemens, E. B., van de Sandt, C., Wong, S. S., Wakim, L. M. & Valkenburg, S. A. Harnessing the power of T cells: the promising hope for a universal influenza vaccine. Vaccines (Basel) 6, 18 (2018).","DOI":"10.3390\/vaccines6020018"},{"key":"32149_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40217-1","volume":"9","author":"VS Mandala","year":"2019","unstructured":"Mandala, V. S., Liao, S. Y., Gelenter, M. D. & Hong, M. The transmembrane conformation of the influenza B virus M2 protein in lipid bilayers. Sci. Rep. 9, 3725 (2019).","journal-title":"Sci. Rep."},{"key":"32149_CR45","doi-asserted-by":"publisher","first-page":"8997","DOI":"10.1074\/jbc.R500020200","volume":"281","author":"LH Pinto","year":"2006","unstructured":"Pinto, L. H. & Lamb, R. A. The M2 proton channels of influenza A and B viruses. J. Biol. Chem. 281, 8997\u20139000 (2006).","journal-title":"J. Biol. Chem."},{"key":"32149_CR46","first-page":"e51112","volume":"6","author":"I Margine","year":"2013","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the Baculovirus Expression System. J. Vis. Exp. 6, e51112 (2013).","journal-title":"J. Vis. Exp."},{"key":"32149_CR47","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1002\/cpmc.100","volume":"57","author":"D Stadlbauer","year":"2020","unstructured":"Stadlbauer, D. et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr. Protoc. Microbiol. 57, e100 (2020).","journal-title":"Curr. Protoc. Microbiol."},{"key":"32149_CR48","doi-asserted-by":"publisher","first-page":"e43603","DOI":"10.1371\/journal.pone.0043603","volume":"7","author":"F Krammer","year":"2012","unstructured":"Krammer, F. et al. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7, e43603 (2012).","journal-title":"PLoS One"},{"key":"32149_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer, M. et al. A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol. Ther. Nucleic Acids 15, 26\u201335 (2019).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"32149_CR50","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/mt.2013.124","volume":"21","author":"MA Maier","year":"2013","unstructured":"Maier, M. A. et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol. Ther. 21, 1570\u20131578 (2013).","journal-title":"Mol. Ther."},{"key":"32149_CR51","doi-asserted-by":"publisher","first-page":"W636","DOI":"10.1093\/nar\/gkz268","volume":"47","author":"F Madeira","year":"2019","unstructured":"Madeira, F. et al. The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47, W636\u2013w641 (2019).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32149-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32149-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32149-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:33:59Z","timestamp":1669314839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32149-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32149"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32149-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"assertion":[{"value":"29 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that NP and YKT are named on a patent describing the use of nucleoside-modified mRNA in lipid nanoparticles as a vaccine platform. NP and FK are named on a patent filed on universal influenza vaccines using nucleoside-modified mRNA. FK is also named on several patents and patent applications for universal influenza virus vaccine candidates based on other vaccine platforms. We have disclosed those interests fully to the University of Pennsylvania and The Icahn School of Medicine at Mount Sinai, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents. MMHS and YKT are employees of Acuitas Therapeutics, a company focused on the development of LNP nucleic acid delivery systems for therapeutic applications. FK has consulted for Merck and Pfizer (before 2020) and currently consults for Pfizer, Seqirus, and Avimex. MM is now employed at Seqirus, Parkville, Australia. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4677"}}